Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (9)
  • Apoptosis
    (3)
  • ALK
    (1)
  • Akt
    (1)
  • Bcl-2 Family
    (1)
  • Caspase
    (1)
  • Necroptosis
    (1)
  • VEGFR
    (1)
  • c-Met/HGFR
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

EGFR IN 9

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    16
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    1
    TargetMol | Natural_Products
EGFR-IN-9
T111631226549-39-8In house
EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R T790M). EGFR-IN-9 has antitumor activity.
  • Inquiry Price
6-8 weeks
Size
QTY
EGFR T790M/L858R-IN-9
T204854
EGFRT790M L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.
  • Inquiry Price
Size
QTY
egfr/her2-in-9
T728541637253-79-2
EGFR HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR T790M mutation.
  • Inquiry Price
6-8 weeks
Size
QTY
Canertinib
PD-183805, CI-1033
T6136267243-28-7
Canertinib (CI-1033) is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
  • Inquiry Price
Size
QTY
EGFR/VEGFR2-IN-3
T201562710972-61-5
EGFR VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2 M phase.
  • Inquiry Price
10-14 weeks
Size
QTY
EGFR-IN-134
T201573
EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2 M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.
  • Inquiry Price
10-14 weeks
Size
QTY
7-oxo Staurosporine
T35423125035-83-8
7-oxo Staurosporine is an antibiotic originally isolated from S. platensis with diverse biological activites. It inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively). 7-oxo Staurosporine induces cell cycle arrest in the G2/M phase in human leukemia K562 cells with a minimal effective dose (MED) of 30 ng/ml. It is cytotoxic to P388 mouse leukemia cells that are resistant and susceptible to doxorubicin . 7-oxo Staurosporine inhibits growth of the mycelial, but not yeast form of C. albicans, C. krusei, C. tropicalis, and C. lusitaniae (MICs = 3.1-25 μg/ml). It increases sphingomyelin synthesis in CHO-K1 cells when used at a concentration of 50 nM.
  • Inquiry Price
Size
QTY
Ensartinib
X-396, X396, Ensacove
T375851370651-20-9
Ensartinib (X-396) is a potent and orally active dual ALK MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).
  • Inquiry Price
1-2 weeks
Size
QTY
WZ8040
T67341214265-57-2
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
  • Inquiry Price
Size
QTY
ProMMP-9 inhibitor-3c
T698752138321-18-1
ProMMP-9 inhibitor-3c is a potent and specific proMMP-9 inhibitor which disrupts f MMP-9 homodimerization and prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR.
  • Inquiry Price
6-8 weeks
Size
QTY
EGFR-IN-25
T731012749562-63-6
EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19 T790M C797S) and 60 nM for A431 cells (WT), respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
PROTAC EGFR degrader 8
T791522925923-46-0
PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells, and inhibits the growth of cell lines H1975, PC-9, and HCC827 with IC50 values of 7.72 nM, 121.9 nM, and 14.21 nM, respectively. This compound is used primarily for cancer research, particularly in the context of non-small cell lung cancer (NSCLC) [1].
  • Inquiry Price
Size
QTY
EGFR-IN-83
T79651
EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50 values of 2.50 μM and 1.96 μM. Furthermore, EGFR-IN-83 is capable of inducing cell apoptosis [1].
  • Inquiry Price
Size
QTY
YS-67
T836262761327-15-3
YS-67 is an orally available, selective and potent EGFR inhibitor with antitumor activity, inhibits p-EGFR and p-AKT, and inhibits the proliferation of A549, PC-9, and A431 cells.YS-67 blocks cell cycle progression and induces apoptosis in the G0 G1 phase, and can be used in the study of non-small-cell lung cancer.
  • Inquiry Price
Size
QTY
EGFR-IN-117
T887853035639-05-2
EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutations, specifically targeting the tumor environment and inducing apoptosis in cancer cells. This compound effectively inhibits the proliferation of H1975, PC-9, and mutant EGFR cells including BaF3-EGFRL858R T790M C797S and BaF3–C797S Del19 T790M, with IC50 values of 13 nM, 19 nM, 1.2 nM, and 1.3 nM respectively. Additionally, EGFR-IN-117 demonstrates anti-tumor activity in mouse models.
  • Inquiry Price
10-14 weeks
Size
QTY
Halociline
TN76992977255-36-8
Halociline, a derivative of alkaloids that can be isolated from the marine fungus Penicillium griseofulvum, targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells. This action is potentially mediated by diverse pathways, including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant, and biofilm inhibitory activities [1] [2].
  • Inquiry Price
Inquiry
Size
QTY